Mon–Thu 8–18, Fri 8–16
In January 2017, we were the first health care provider in Finland to use 177-lutetium-PSMA isotope therapy in the treatment of advanced prostate cancer, which enables destroying metastases outside the bones efficiently without any severe adverse effects.
Before the treatment, we carry out a diagnostic PET scan using F-PSMA tracers to ensure that 177-lutetium-PSMA uptake occurs in the metastases.
177-lutetium-PSMA therapies are administered intravenously, and its their most common side effect is a dry mouth. Depending on the individual, the treatment is typically performed 2–6 times approximately every 4–6 weeks (177-lutetium-PSMA).
The multidisciplinary team in charge of peptide-receptor therapies at Docrates Cancer Center is led by Chief Physician in Nuclear Medicine Jukka Kemppainen.
The VISION study results* were presented in ESMO2021 conference: the results showed that treatment with 177-lutetium-PSMA significantly improved overall survival (OS) in patients with PSMA-positive metastatic castration-resistant prostate cancer.
*Publiced in NEJM September 2021
New forms of treatment based on molecular diagnostics enable more and more patients to completely recover from cancer, and make...
Read more
With a transaction signed on 2 September 2024, Mehiläinen has acquired Docrates Ltd, as a result of which Docrates Cancer...
On 27, August 2024, the Finnish Competition and Consumer Authority (FCCA) approved the merger of Mehiläinen and Docrates Cancer Center....
Breast cancer is a serious disease that requires individual care and expertise. As part of cancer treatment, the patient may...
Contact us!
Mon-Thu 8:00-18:00, Fri 8:00-16:00
